These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21766263)

  • 1. [Molecular mechanisms of hepatitis C virus (HCV) replication - implications for the development of antiviral drugs].
    Bühler S; Bartenschlager R
    Z Gastroenterol; 2011 Jul; 49(7):836-44. PubMed ID: 21766263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibitors of hepatitis C virus replication.
    Neyts J
    Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
    Suzuki T
    Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.
    Gentzsch J; Hinkelmann B; Kaderali L; Irschik H; Jansen R; Sasse F; Frank R; Pietschmann T
    Antiviral Res; 2011 Feb; 89(2):136-48. PubMed ID: 21167208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.
    Watashi K; Hijikata M; Hosaka M; Yamaji M; Shimotohno K
    Hepatology; 2003 Nov; 38(5):1282-8. PubMed ID: 14578868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction networks of hepatitis C virus NS4B: implications for antiviral therapy.
    Li S; Yu X; Guo Y; Kong L
    Cell Microbiol; 2012 Jul; 14(7):994-1002. PubMed ID: 22329740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host factors involved in the replication of hepatitis C virus.
    Moriishi K; Matsuura Y
    Rev Med Virol; 2007; 17(5):343-54. PubMed ID: 17563922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental models for hepatitis C viral infection.
    Boonstra A; van der Laan LJ; Vanwolleghem T; Janssen HL
    Hepatology; 2009 Nov; 50(5):1646-55. PubMed ID: 19670425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors.
    von Hahn T; Ciesek S; Manns MP
    Discov Med; 2011 Sep; 12(64):237-44. PubMed ID: 21955851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
    Watashi K; Shimotohno K
    Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-hepatitis C virus activity of Acacia confusa extract via suppressing cyclooxygenase-2.
    Lee JC; Chen WC; Wu SF; Tseng CK; Chiou CY; Chang FR; Hsu SH; Wu YC
    Antiviral Res; 2011 Jan; 89(1):35-42. PubMed ID: 21075144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiviral treatment of chronic hepatitis C].
    Berger A
    Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
    Nozaki A; Morimoto M; Kondo M; Oshima T; Numata K; Fujisawa S; Kaneko T; Miyajima E; Morita S; Mori K; Ikeda M; Kato N; Tanaka K
    Arch Virol; 2010 Apr; 155(4):601-5. PubMed ID: 20204428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems.
    Gottwein JM; Bukh J
    Adv Virus Res; 2008; 71():51-133. PubMed ID: 18585527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.